Controlled glycosylation of plant-produced recombinant proteins.

Despite their recognized importance for therapeutic proteins, the production of structurally defined glycans is still a challenging issue. However, an increased understanding of glycosylation pathways, recent advances in analytical tools, and emerging technologies for subcellular targeting using chimeric glycosyltransferases are facilitating the rational design of new glycan biosynthetic pathways. Plants are particularly amenable to glyco-engineering approaches and thus they are increasingly being used for the production of recombinant proteins. Here we summarize the main achievements in the field of in planta glyco-engineering for the production of therapeutically relevant proteins.

[1]  Martin Pabst,et al.  Glycan analysis by modern instrumental methods , 2011, Proteomics.

[2]  S. Botchway,et al.  Time-Resolved Fluorescence Imaging Reveals Differential Interactions of N-Glycan Processing Enzymes across the Golgi Stack in Planta1[W][OA] , 2013, Plant Physiology.

[3]  A. Varki.  Nothing in Glycobiology Makes Sense, except in the Light of Evolution , 2006, Cell.

[4]  Renate Kunert,et al.  In Planta Protein Sialylation through Overexpression of the Respective Mammalian Pathway* , 2010, The Journal of Biological Chemistry.

[5]  C. Stemmer,et al.  In vivo glyco‐engineered antibody with improved lytic potential produced by an innovative non‐mammalian expression system , 2007, Biotechnology journal.

[6]  J. Stadlmann,et al.  Mass + retention time = structure: a strategy for the analysis of N-glycans by carbon LC-ESI-MS and its application to fibrin N-glycans. , 2007, Analytical chemistry.

[7]  N. Callewaert,et al.  Production of Complex Multiantennary N-Glycans in Nicotiana benthamiana Plants1[W][OA] , 2011, Plant Physiology.

[8]  P. Lerouge,et al.  N-Glycoprotein biosynthesis in plants: recent developments and future trends , 1998, Plant Molecular Biology.

[9]  Sylvestre Marillonnet,et al.  Fast track assembly of multigene constructs using Golden Gate cloning and the MoClo system , 2012 .

[10]  J. Marth,et al.  Glycosylation in Cellular Mechanisms of Health and Disease , 2006, Cell.

[11]  G. Grabowski,et al.  Taliglucerase alfa: an enzyme replacement therapy using plant cell expression technology. , 2014, Molecular genetics and metabolism.

[12]  F. Altmann,et al.  Generation of Biologically Active Multi-Sialylated Recombinant Human EPOFc in Plants , 2013, PloS one.

[13]  N. Bohorova,et al.  Enhanced potency of a fucose-free monoclonal antibody being developed as an Ebola virus immunoprotectant , 2011, Proceedings of the National Academy of Sciences.

[14]  G. Rouwendal,et al.  Efficient introduction of a bisecting GlcNAc residue in tobacco N-glycans by expression of the gene encoding human N-acetylglucosaminyltransferase III. , 2007, Glycobiology.

[15]  Johannes S. Gach,et al.  Fc-Glycosylation Influences Fcγ Receptor Binding and Cell-Mediated Anti-HIV Activity of Monoclonal Antibody 2G12 , 2010, The Journal of Immunology.

[16]  A. Granell,et al.  GoldenBraid: An Iterative Cloning System for Standardized Assembly of Reusable Genetic Modules , 2011, PloS one.

[17]  L. Tu,et al.  Localization of Golgi-resident glycosyltransferases , 2009, Cellular and Molecular Life Sciences.

[18]  G. Stiegler,et al.  Generation of glyco-engineered Nicotiana benthamiana for the production of monoclonal antibodies with a homogeneous human-like N-glycan structure. , 2008, Plant biotechnology journal.

[19]  N. Callewaert,et al.  Production of Plant Made Pharmaceuticals: From Plant Host to Functional Protein , 2012 .

[20]  Daniel Kolarich,et al.  Determination of site-specific glycan heterogeneity on glycoproteins , 2012, Nature Protocols.

[21]  J. Tavernier,et al.  Biologically active, magnICON®-expressed EPO-Fc from stably transformed Nicotiana benthamiana plants presenting tetra-antennary N-glycan structures. , 2012, Journal of biotechnology.

[22]  R. Van Ree,et al.  An antibody produced in tobacco expressing a hybrid β-1,4-galactosyltransferase is essentially devoid of plant carbohydrate epitopes , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[23]  T. Mor,et al.  Expression of human butyrylcholinesterase with an engineered glycosylation profile resembling the plasma-derived orthologue. , 2014, Biotechnology journal.

[24]  F. Altmann,et al.  Construction of a Functional CMP-Sialic Acid Biosynthesis Pathway in Arabidopsis1[OA] , 2008, Plant Physiology.

[25]  D. Bosch,et al.  N-glycosylation of plant-produced recombinant proteins. , 2013, Current pharmaceutical design.

[26]  H. Kozutsumi,et al.  Relationship between sugar chain structure and biological activity of recombinant human erythropoietin produced in Chinese hamster ovary cells. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[27]  S. Yoshida,et al.  Stable expression of human beta1,4-galactosyltransferase in plant cells modifies N-linked glycosylation patterns. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[28]  H. Steinkellner,et al.  IgG-Fc glycoengineering in non-mammalian expression hosts , 2012, Archives of biochemistry and biophysics.

[29]  J. Stadlmann,et al.  A Unique β1,3-Galactosyltransferase Is Indispensable for the Biosynthesis of N-Glycans Containing Lewis a Structures in Arabidopsis thaliana[W][OA] , 2007, The Plant Cell Online.

[30]  E. Bennett,et al.  Toward Stable Genetic Engineering of Human O-Glycosylation in Plants1[C][W][OA] , 2012, Plant Physiology.

[31]  R. Reski,et al.  Moss-based production of asialo-erythropoietin devoid of Lewis A and other plant-typical carbohydrate determinants. , 2012, Plant biotechnology journal.

[32]  P. Lerouge,et al.  Transient co-expression for fast and high-yield production of antibodies with human-like N-glycans in plants. , 2009, Plant biotechnology journal.

[33]  F. Altmann.  The Role of Protein Glycosylation in Allergy , 2006, International Archives of Allergy and Immunology.

[34]  F. Altmann,et al.  N-Glycosylation engineering of plants for the biosynthesis of glycoproteins with bisected and branched complex N-glycans , 2011, Glycobiology.

[35]  Laura Neumann,et al.  Engineering of Sialylated Mucin-type O-Glycosylation in Plants , 2012, The Journal of Biological Chemistry.

[36]  P. Lerouge,et al.  Immunoreactivity in mammals of two typical plant glyco-epitopes, core alpha(1,3)-fucose and core xylose. , 2003, Glycobiology.

[37]  S. Toegel,et al.  Isomeric analysis of oligomannosidic N-glycans and their dolichol-linked precursors. , 2012, Glycobiology.

[38]  M. Ratner.  Genentech's glyco-engineered antibody to succeed Rituxan. , 2014, Nature biotechnology.

[39]  Daniel Kolarich,et al.  Glycomics, glycoproteomics and the immune system. , 2012, Current opinion in chemical biology.

[40]  P. Lerouge,et al.  Galactose-extended glycans of antibodies produced by transgenic plants , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[41]  H. Steinkellner,et al.  Glyco‐engineering in plants to produce human‐like N‐glycan structures , 2012, Biotechnology journal.

[42]  Y. Gleba,et al.  Plant viral vectors for delivery by Agrobacterium. , 2014, Current topics in microbiology and immunology.

[43]  O. Bohorov,et al.  Glycan variants of a respiratory syncytial virus antibody with enhanced effector function and in vivo efficacy , 2014, Proceedings of the National Academy of Sciences.

[44]  N. Callewaert,et al.  N-glycosylation engineering of biopharmaceutical expression systems. , 2009, Current molecular medicine.

[45]  V. Gomord,et al.  The presence of Lewis a epitopes in Arabidopsis thaliana glycoconjugates depends on an active alpha4-fucosyltransferase gene. , 2002, Glycobiology.